Telaprevir for HIV/Hepatitis C Virus-Coinfected Patients Failing Treatment With Pegylated Interferon/Ribavirin (ANRS HC26 TelapreVIH): An Open-Label, Single-Arm, Phase 2 Trial | Zendy

L. Cotte | Zendy; Joerg E. Braun | Zendy; C. Lascoux-Combe | Zendy; Corine Vincent | Zendy; MarcAntoine Valantin | Zendy; P. Sogni | Zendy; Karine Lacombe | Zendy; D. Neau | Zendy; H. Aumaitre | Zendy; Dominique Batisse | Zendy; P. de Truchis | Zendy; A. Gervais | Zendy; C. Michelet | Zendy; Philippe Morlat | Zendy; Daniel Vittecoq | Zendy; Isabelle Rosa | Zendy; Inga Bertucci | Zendy; Stéphane Chevaliez | Zendy; J.-P. Aboulker | Zendy; JeanMichel Molina | Zendy; Lise Bernard | Zendy; Arnaud Chéret | Zendy; Laurent Cotte | Zendy; P. Dellamonica | Zendy; Stéphanie Dominguez | Zendy; Pierre Marie Girard | Zendy; F. Lucht | Zendy; Sophie Métivier | Zendy; GeorgesPhilippe Pageaux | Zendy; Stanislas Pol | Zendy; Eric S. Rosenthal | Zendy; David Zucman | Zendy

Open Access

Telaprevir for HIV/Hepatitis C Virus-Coinfected Patients Failing Treatment With Pegylated Interferon/Ribavirin (ANRS HC26 TelapreVIH): An Open-Label, Single-Arm, Phase 2 Trial

Author(s) -

L. Cotte,

Joerg E. Braun,

C. Lascoux-Combe,

Corine Vincent,

MarcAntoine Valantin,

P. Sogni,

Karine Lacombe,

D. Neau,

H. Aumaitre,

Dominique Batisse,

P. de Truchis,

A. Gervais,

C. Michelet,

Philippe Morlat,

Daniel Vittecoq,

Isabelle Rosa,

Inga Bertucci,

Stéphane Chevaliez,

J.-P. Aboulker,

JeanMichel Molina,

Lise Bernard,

Arnaud Chéret,

Laurent Cotte,

P. Dellamonica,

Stéphanie Dominguez,

Pierre Marie Girard,

F. Lucht,

Sophie Métivier,

GeorgesPhilippe Pageaux,

Stanislas Pol,

Eric S. Rosenthal,

David Zucman

Publication year - 2014

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1093/cid/ciu659

Subject(s) - medicine , ribavirin , pegylated interferon , telaprevir , efavirenz , emtricitabine , population , hepatitis c virus , virology , gastroenterology , regimen , hepatitis c , viral load , lamivudine , hepatitis b virus , virus , environmental health , antiretroviral therapy

Retreatment with pegylated interferon (peg-IFN) and ribavirin (RBV) results in poor sustained virological response (SVR) rates in human immunodeficiency virus (HIV)/hepatitis C virus (HCV)-coinfected patients. There are limited data regarding the use of telaprevir plus peg-IFN/RBV in this population.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research